With Europe’s wearable medical device market expected to more than double its 2015 value by 2020, it is critical that medical original equipment manufacturers (OEMs) are launching products that are safe, reliable and effective. Here, Michele Windsor, global marketing manager of medical battery manufacturer Accutronics, explains the role batteries play in this


hile he may have co-founded Intel, Gordon Moore’s greatest

contribution to the world, and particularly the electronics industry, is Moore’s law; the 1965 observation and prediction that the number of transistors on an integrated circuit increases by a factor of two every two years. It may have been a prediction when

Moore published his paper in 1965, but it’s since become more of a benchmark for the electronics industry. This has never been more apparent than it has since the turn of the century, where we’ve seen technology from personal computers and mobile phones to cardiac monitoring equipment shrink in size but increase in functionality and power. It is these developments in electronics

that have led to the rapid rise of wearable devices, particularly in critical sectors such as healthcare and medical technology (MedTech). According to research firm Market Data

Forecast, Europe’s wearable medical device market was valued at $1.37bn in 2015 and, based on the company’s estimates from late 2016, is expected to grow to $3.34bn by 2020. This ushers in an exciting time for medical OEMs, but only if design engineers make the right decisions. With a rapidly growing market comes an opportunity for wearable medtech OEMs to develop effective equipment that adds value to their business. This doesn’t necessarily mean pushing the boundaries of wearable medtech with every new product; it can be as simple as doing the right things exceptionally well. For wearable medical devices, this will

mean selecting the right components that can overcome the typical challenges of medtech. Accutronics has worked closely with medical OEMs for many years and during this time we’ve observed that the biggest challenges come from product life and device run time. Fortunately, these issues can be easily

addressed. The challenge for design engineers is identifying the right time to consult with a medical battery specialist


to ensure the problems can be overcome in the most effective way. The general rule is: the sooner, the better. For example, Accutronics is currently

working with design engineers at wearable medtech OEMs across Europe to bring the pouch-cell batteries manufactured by our US parent company, Ultralife Corporation, into the market. The Thin Cell range of non- rechargeable primary batteries are suitable for wearable devices and drug delivery systems. These batteries are said to outperform traditional lithium coin cells, both in terms of energy density rating, up to 400Wh/kg for a longer run time, and a higher retention of capacity when stored. This helps avoid the passivation that can make stored lithium coin cell batteries unreliable. However, certain wearable devices will

Fingerprint drug test simplifies ‘Duty of Care’ Accutronics

demand rechargeable batteries. For these projects, design engineers must consult with battery manufacturers as early in the product development process as I

ntelligent Fingerprinting is providing new levels of convenience, hygiene and speed to workplace drug

testing for the manufacturing industry with the availability of a simple, end-to-end drug testing solution based on fingerprint sweat analysis. Unlike traditional urine or saliva-based drug

tests that can be invasive, time-consuming and undignified for testers and employees, the portable Intelligent Fingerprinting drug testing solution is claimed to be quick and easy to deploy wherever it is needed across a manufacturer’s own operation or their extended supply chain. The fingerprint-based system supports all forms of workplace drug testing, including pre-employment screening as well as random and for-cause testing, whether in the office or before/after shifts for production line workers, heavy machinery operators, forklift or delivery drivers. The new end-to-end system features an initial

screening test that works by analysing sweat from a fingerprint to determine if an employee has recently used cocaine, opiates, amphetamines or cannabis. Sample collection takes only five

possible. Introducing the battery specifications at the initial design stages will avoid redesign costs and performance issues during use. By doing this, design engineers can ensure they design and manufacture a better quality of product that will meet the growing demand and expectation of wearable medtech. These demands are the same for end users and OEMs alike: an assurance of safety, reliability and effectiveness. Battery selection plays a pivotal role in that and design engineers must choose carefully and consult with specialists to ensure the best result for the device, the market and the user. For more information on battery

selection in the medical device market, read Accutronics’ latest whitepaper, available to download from uploads/whitepaper_healthcare1.pdf

T: 01782 566 622

seconds, with simultaneous screening results for all four drug groups provided in just eight minutes. Should an employee or contractor’s initial screen

provide a positive result for any of the four drugs tested, in contravention of a manufacturing firm’s existing Health & Safety or drug misuse policy, the tester would then use Intelligent Fingerprinting’s Fingerprint Collection Kit for Laboratory Analysis to collect samples for a confirmation test. The kit for the laboratory confirmation service includes everything required to securely send the collected samples to the testing laboratory, including a tamper-evident security bag, barcodes to maintain anonymous sample identity and a postage-paid returns envelope.

Intelligent Fingerprinting


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44